Roth Capital Starts AcelRx Pharmaceuticals (ACRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- US stock futures advance as strong AI-linked earnings continue
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Jefferies Sees Zalviso Upside for AcelRx (ACRX) Following Pain Survey
April 16, 2014 6:58 AM EDTJefferies analyst Biren Amin reiterated a Buy rating and $17 price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) following a physician survey which offered an optimistic upside scenario for Zalviso.
Amin commented, "We recently surveyed 43 physicians which currently prescribe IV patient-controlled analgesia to their... More
Jefferies Assumes AcelRx Pharmaceuticals (ACRX) at Buy
April 10, 2014 6:33 AM EDTJefferies assumes coverage on AcelRx Pharmaceuticals (NASDAQ: ACRX) with a Buy rating and a price target of $17.00 (from $15.00).
Analyst Biren Amin said, "We expect FDA approval of Zalviso, a treatment for moderate to severe pain in post-surgical patients, on its PDUFA Jul 27... More
